Low risk papillary thyroid cancer

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Brito, Juan P ^a   Hay, Ian D ^a   Morris, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RADIOACTIVE IODINE; THYROTROPIN;

CANCER STAGING; DISEASE CARRIER; DISEASE COURSE; ENDOSCOPIC SURGERY; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTHYROIDISM; INCIDENCE; IONIZING RADIATION; LASER SURGERY; LOW RISK PATIENT; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MINIMALLY INVASIVE PROCEDURE; NECK DISSECTION; OBSERVATIONAL STUDY; OSTEOLYSIS; PARATHYROID FUNCTION; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; ROBOTIC THYROIDECTOMY; ROBOTICS; SUBTOTAL THYROIDECTOMY; SURVIVAL RATE; THYROID CANCER; THYROIDECTOMY; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; TUMOR ABLATION; ULTRASOUND GUIDED PERCUTANEOUS ETHANOL ABLATION;

CARCINOMA; ENDOSCOPY; ETHANOL; GENETIC MARKERS; HUMANS; INCIDENCE; INDIVIDUALIZED MEDICINE; IODINE RADIOISOTOPES; LYMPH NODE EXCISION; MUTATION; NEOPLASM STAGING; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; SCLEROSING SOLUTIONS; SCLEROTHERAPY; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; TUMOR MARKERS, BIOLOGICAL; WATCHFUL WAITING;

EID: 84902602771     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g3045     Document Type: Review

References (99)

1. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997;126:226-31. (Pubitemid 27061578)
2. Reiners C, Wegscheider K, Schicha H, Theissen P, Vaupel R, Wrbitzky R, et al. Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees. Thyroid 2004;14:926-32. (Pubitemid 39612911)
3. Braunstein G, Sacks W. Thyroid nodules. In: Braunstein GD, ed. Thyroid cancer. Springer US, 2012:45-61.
4. Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM. Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis. Thyroid 2013;23:449-55.
5. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 1985;56:531-8. (Pubitemid 15035581)
6. American Cancer Society. Cancer facts and figures 2012. www.cancer.org/acs/groups/content/epidemiologysurveilance/documents/document/ acspc-031941.pdf.
7. Roti E, degli Uberti EC, Bondanelli M, Braverman LE. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol 2008;159:659-73.
8. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
9. Pitoia F, Ward L, Wohllk N, Friguglietti C, Tomimori E, Gauna A, et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol 2009;53:884-7.
10. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803. (Pubitemid 43997716)
11. Harris PE. The management of thyroid cancer in adults: a review of new guidelines. Clin Med 2002;2:144-6. (Pubitemid 34498830)
12. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-7; discussion 57-8.
13. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:1028-34. (Pubitemid 34014569)
14. Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004;45:988-94. (Pubitemid 47611686)
15. Rouxel A, Hejblum G, Bernier MO, Boelle PY, Menegaux F, Mansour G, et al. Prognostic factors associated with the survival of patients developing locoregional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2004;89:5362-8. (Pubitemid 39518409)
16. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 2000;7:229-39. (Pubitemid 30387658)
17. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-95. (Pubitemid 18010757)
18. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104:947-53. (Pubitemid 19011971)
19. American Joint Committee on Cancer. Thyroid. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual. 7th ed. Springer, 2010:87-96.
20. Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM. Outcome of patients with differentiated thyroid cancer risk stratified according to the American Thyroid Association and Latin-American Thyroid Society risk of recurrence classification systems. Thyroid 2013;23:1401-7.
21. Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 2011;165:441-6.
22. Jeon MJ, Kim WG, Park WR, Han JM, Kim TY, Song DE, et al. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. Eur J endocrinol 2014;170:23-30.
23. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;381:1058-69.
24. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 2012;91:274-86.
25. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013;309:1493-501.
26. Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg 2013;139:1164-70.
27. Ito Y, Yoshida H, Kihara M, Kobayashi K, Miya A, Miyauchi A. BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients? World J Surg 2014;38:679-87.
28. Cappola AR, Mandel SJ. Molecular testing in thyroid cancer: BRAF mutation status and mortality. JAMA 2013;309:1529-30.
29. Melo M, Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 2014;99:E754-65.
30. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer incidence in five continents. Vol IX. IARC Scientific Publications No. 160. International Agency for Research on Cancer, 2007. www.iarc.fr/en/publications/ pdfs-online/epi/sp160/.
31. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 2009;20:525-31.
32. Lee TJ, Kim S, Cho HJ, Lee JH. The incidence of thyroid cancer is affected by the characteristics of a healthcare system. J Korean Med Sci 2012;27:1491-8.
33. Davies L, Welch H. Current thyroid cancer trends in the united states. JAMA Otolaryngol Head Neck Surg 2014;140:317-22.
34. Kweon SS, Shin MH, Chung IJ, Kim YJ, Choi JS. Thyroid cancer is the most common cancer in women, based on the data from population-based cancer registries, South Korea. Jpn J Clin Oncol 2013;43:1039-46.
35. Ferlay J, Parkin DM, Curado MP, Bray F, Edwards B, Shin HR, et al. Cancer incidence in five continents. Vol I-IX: IARC CancerBase No. 9. International Agency for Research on Cancer, 2010. http://ci5.iarc.fr.
36. Van den Bruel A, Francart J, Dubois C, Adam M, Vlayen J, De Schutter H, et al. Regional variation in thyroid cancer incidence in Belgium is associated with variation in thyroid imaging and thyroid disease management. J Clin Endocrinol Metab 2013;98:4063-71.
37. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7.
38. Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ 2013;347:f4706.
39. Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C. Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer 1993;71:4022-9. (Pubitemid 23172986)
40. Malone MK, Zagzag J, Ogilvie JB, Patel KN, Heller KS. Thyroid cancers detected by imaging are not necessarily small or early stage. Thyroid 2014;24:314-8.
41. Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 2013;23:885-91.
42. Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol 2008;81:362-78. (Pubitemid 351743850)
43. Negri E, Ron E, Franceschi S, Dal Maso L, Mark SD, Preston-Martin S, et al. A pooled analysis of case-control studies of thyroid cancer. I. Methods. Cancer Causes Control 1999;10:131-42. (Pubitemid 29161105)
44. Dal Maso L, Bosetti C, La Vecchia C, Franceschi S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control 2009;20:75-86.
45. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007;246:375-81; discussion 81-4.
46. Carling T, Carty SE, Ciarleglio MM, Cooper DS, Doherty GM, Kim LT, et al. American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid 2012;22:237-44.
47. Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002;26:22-8. (Pubitemid 36918813)
48. Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 2003;237:399-407. (Pubitemid 38176456)
49. Gulben K, Berberoglu U, Celen O, Mersin HH. Incidental papillary microcarcinoma of the thyroid - factors affecting lymph node metastasis. Langenbecks Arch Surg 2008;393:25-9. (Pubitemid 350196885)
50. Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery 2010;148:1100-6; discussion 006-7.
51. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 2006;140:1000-5; discussion 1005-7.
52. Zetoune T, Keutgen X, Buitrago D, Aldailami H, Shao H, Mazumdar M, et al. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann Surg Oncol 2010;17:3287-93.
53. Lang BH, Ng SH, Lau LL, Cowling BJ, Wong KP, Wan KY. A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy. Thyroid 2013;23:1087-98.
54. Tisell LE, Nilsson B, Molne J, Hansson G, Fjalling M, Jansson S, et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg 1996;20:854-9. (Pubitemid 26281914)
55. Salvesen H, Njolstad PR, Akslen LA, Albrektsen G, Viste A, Soreide O, et al. Thyroid carcinoma: results from surgical treatment in 211 consecutive patients. Eur J Surg 1991;157:521-6.
56. Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg 2007;245:604-10. (Pubitemid 46555665)
57. Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg 2010;136:1055-61.
58. Shaha AR, Shah JP, Loree TR. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol 1997;4:328-33. (Pubitemid 127725237)
59. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53 856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 1998;83:2638-48. (Pubitemid 29019586)
60. Farkas EA, King TA, Bolton JS, Fuhrman GM. A comparison of total thyroidectomy and lobectomy in the treatment of dominant thyroid nodules. Am Surg 2002;68:678-82; discussion 82-3.
61. Henry JF, Gramatica L, Denizot A, Kvachenyuk A, Puccini M, Defechereux T. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 1998;383:167-9. (Pubitemid 28442533)
62. Palestini N, Borasi A, Cestino L, Freddi M, Odasso C, Robecchi A. Is central neck dissection a safe procedure in the treatment of papillary thyroid cancer? Our experience. Langenbecks Arch Surg 2008;393:693-8.
63. Roh JL, Park JY, Park CI. Prevention of postoperative hypocalcemia with routine oral calcium and vitamin D supplements in patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection. Cancer 2009;115:251-8.
64. Keston AS, Ball RP, Frantz VK, Palmer WW. Storage of radioactive iodine in a metastasis from thyroid carcinoma. Science 1942;95:362-3.
65. Blahd WH, Nordyke RA, Bauer FK. Radioactive iodine (I 131) in the postoperative treatment of thyroid cancer. Cancer 1960;13:745-56.
66. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26:879-85. (Pubitemid 36920280)
67. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol 2006;94:692-700. (Pubitemid 44902068)
68. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668-76. (Pubitemid 39089119)
69. Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid 2010;20:1235-45.
70. Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 2008;144:980-7; discussion 87-8.
71. Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffe S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab 2012;97:1526-35.
72. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 2011;117:4439-46.
73. Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ. Use of radioactive iodine for thyroid cancer. JAMA 2011;306:721-8.
74. Durante C, Montesano T, Attard M, Torlontano M, Monzani F, Costante G, et al. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J Clin Endocrinol Metab 2012;97:2748-53.
75. Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin Endocrinol Metab 2008;93:1167-9. (Pubitemid 351519702)
76. Dunhill TP. Surgery of the thyroid gland. BMJ 1937;1:460-61. www.bmj.com/content/1/3975/568.
77. McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002;34:554-64. (Pubitemid 36113813)
78. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the national thyroid cancer treatment cooperative registry. Thyroid 1998;8:737-44. (Pubitemid 28535681)
79. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996;81:4318-23. (Pubitemid 26412036)
80. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229-42. (Pubitemid 46080167)
81. Bauer DC, Rodondi N, Stone KL, Hillier TA. Thyroid hormone use, hyperthyroidism and mortality in older women. Am J Med 2007;120:343-9. (Pubitemid 46483309)
82. Kung AW, Yeung SS. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 1996;81:1232-6. (Pubitemid 26083997)
83. Sgourakis G, Sotiropoulos GC, Neuhauser M, Musholt TJ, Karaliotas C, Lang H. Comparison between minimally invasive video-assisted thyroidectomy and conventional thyroidectomy: is there any evidence-based information? Thyroid 2008;18:721-7. (Pubitemid 352009935)
84. FDA. Form FDA-483. 2013. www.fda.gov/downloads/AboutFDA/CentersOffices/ OfficeofGlobalRegulatoryOperationsandPolicy/ORA/ORAElectronicReadingRoom/ UCM358468.pdf.
85. Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol 2002;178:699-704. (Pubitemid 34178153)
86. Hay ID, Lee RA, Davidge-Pitts C, Reading CC, Charboneau JW. Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected "recurrent" neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and (131)I therapy. Surgery 2013;154:1448-55.
87. Hay ID, Lee RA. Ultrasound-guided percutaneous ethanol ablation represents a promising minimally invasive alternative to observation in papillary thyroid microcarcinoma. Abstracts of the 83rd Annual Meeting of the American Thyroid Association Meeting. October 16-20, 2013. San Juan, Puerto Rico. Thyroid 2013;23(suppl 1):A-58:129.
88. Guglielmi R, Pacella CM, Bianchini A, Bizzarri G, Rinaldi R, Graziano FM, et al. Percutaneous ethanol injection treatment in benign thyroid lesions: role and efficacy. Thyroid 2004;14:125-31. (Pubitemid 38375499)
89. Papini E, Guglielmi R, Gharib H, Misischi I, Graziano F, Chianelli M, et al. Ultrasound-guided laser ablation of incidental papillary thyroid microcarcinoma: a potential therapeutic approach in patients at surgical risk. Thyroid 2011;21:917-20.
90. Pacella CM, Bizzarri G, Guglielmi R, Anelli V, Bianchini A, Crescenzi A, et al. Thyroid tissue: US-guided percutaneous interstitial laser ablation-a feasibility study. Radiology 2000;217:673-7.
91. Valcavi R, Piana S, Stecconi Bortolani G, Lai R, Barbieri V, Negro R. Ultrasound-guided percutaneous laser ablation of thyroid papillary microcarcinoma (PMC). a feasibility study on 3 cases with pathological and immunohistochemical evaluation. Thyroid 2013;23:1578-82.
92. Fuller CW, Nguyen SA, Lohia S, Gillespie MB. Radiofrequency ablation for treatment of benign thyroid nodules: systematic review. Laryngoscope 2014;124:346-53.
93. Shin JE, Baek JH, Lee JH. Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges. Curr Opin Oncol 2013;25:14-9.
94. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014;24:27-34.
95. Sugitani I, Toda K, Yamada K, Yamamoto N, Ikenaga M, Fujimoto Y. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 2010;34:1222-31.
96. Pace MD, Fagin JA, Bach A, Boucai L, Minkowitz G, Morris LG, et al. Properly selected patients with papillary thyroid cancer readily accept active surveillance when offered as a standard of care alternative to immediate surgery. Abstracts of the 83rd Annual Meeting of the American Thyroid Association Meeting. October 16-20, 2013. San Juan, Puerto Rico. Thyroid 2013;23(suppl 1):A-116:8.
97. Robenshtok E, Fish S, Bach A, Dominguez JM, Shaha A, Tuttle RM. Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. J Clin Endocrinol Metab 2012;97:2706-13.
98. Rondeau G, Fish S, Hann LE, Fagin JA, Tuttle RM. Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. Thyroid 2011;21:845-53.
99. Ross JA SR, Pollock BH, Robison LL. Childhood cancer in the United States. A geographical analysis of cases from the Pediatric Cooperative Clinical Trials groups. Cancer 1996;77:201-7. (Pubitemid 26002758)